WO2001007033A3 - Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline - Google Patents

Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline Download PDF

Info

Publication number
WO2001007033A3
WO2001007033A3 PCT/HU2000/000084 HU0000084W WO0107033A3 WO 2001007033 A3 WO2001007033 A3 WO 2001007033A3 HU 0000084 W HU0000084 W HU 0000084W WO 0107033 A3 WO0107033 A3 WO 0107033A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluoroselegiline
reparations
neuroprotective pharmaceutical
neuroprotective
pharmaceutical
Prior art date
Application number
PCT/HU2000/000084
Other languages
French (fr)
Other versions
WO2001007033A2 (en
Inventor
Attila Di Baranyi
Peter Aranyi
Franciska Erdoe
Mihalka Csilla Schrammelne
Losonczi Olga Venekeine
Original Assignee
Chinoin Gyogyszer Es Vegyeszet
Baranyi Attilane Hf
Baranyi Krisztina Hf
Peter Aranyi
Franciska Erdoe
Mihalka Csilla Schrammelne
Losonczi Olga Venekeine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszet, Baranyi Attilane Hf, Baranyi Krisztina Hf, Peter Aranyi, Franciska Erdoe, Mihalka Csilla Schrammelne, Losonczi Olga Venekeine filed Critical Chinoin Gyogyszer Es Vegyeszet
Priority to AU65856/00A priority Critical patent/AU6585600A/en
Publication of WO2001007033A2 publication Critical patent/WO2001007033A2/en
Publication of WO2001007033A3 publication Critical patent/WO2001007033A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the use of racemic or optically active p-fluoro-selegiline and/or its salts of formula (I) for the protection of neurons and/or for the promotion of the regeneration of damaged neurons.
PCT/HU2000/000084 1999-07-22 2000-07-21 Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline WO2001007033A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65856/00A AU6585600A (en) 1999-07-22 2000-07-21 Neuroprotective pharmaceutical preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9902482A HUP9902482A2 (en) 1999-07-22 1999-07-22 Use of p-fluoro-selegiline for producing neuroprotective pharmaceutical compositions
HUP9902482 1999-07-22

Publications (2)

Publication Number Publication Date
WO2001007033A2 WO2001007033A2 (en) 2001-02-01
WO2001007033A3 true WO2001007033A3 (en) 2001-08-16

Family

ID=89998823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2000/000084 WO2001007033A2 (en) 1999-07-22 2000-07-21 Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline

Country Status (3)

Country Link
AU (1) AU6585600A (en)
HU (1) HUP9902482A2 (en)
WO (1) WO2001007033A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960797A (en) * 1984-05-31 1990-10-02 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof
WO1993012775A1 (en) * 1991-12-20 1993-07-08 Chinoin Gyógyszer- És Vegyészeti Termékek Gyára Rt. Pharmaceutical composition and process for the preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960797A (en) * 1984-05-31 1990-10-02 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof
WO1993012775A1 (en) * 1991-12-20 1993-07-08 Chinoin Gyógyszer- És Vegyészeti Termékek Gyára Rt. Pharmaceutical composition and process for the preparation thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. TERLECKYJ ET AL: "In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl", ANNALS OF THE NEW YORK ACADEMY OF SCIENCE, vol. 648, 1992, pages 365 - 367, XP000981825 *
F. ERDO ET AL: "Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils", NEUROREPORT, vol. 11, no. 11, 3 August 2000 (2000-08-03), pages 2597 - 2600, XP000981833 *
K. MAGYAR ET AL: "Neuroprotective and neuronal rescue effcets of selegiline: review", NEUROBIOLOGY., vol. 7, no. 2, 1999, AKADEMIAI KIADO, BUDAPEST., HU, pages 175 - 190, XP000981826, ISSN: 1216-8063 *
KNOLL J ET AL: "(-)DEPRENYL AND (-)PARAFLUORODEPRENYL-TREATMENT PREVENTS AGE-RELATED PIGMENT CHANGES IN THE SUBSTANTIA NIGRA. A TV-IMAGE ANALYSIS OF NEUROMELANIN", MECHANISMS OF AGEING AND DEVELOPMENT,ELSEVIER SEQUOIA, LAUSANNE,,CH, vol. 63, no. 2, 1992, pages 157 - 163, XP000653658 *
MAGYAR K: "BEHAVIOUR OF (-)-DEPRENYL AND ITS ANALOGUES", JOURNAL OF NEURAL TRANSMISSION,XX,XX, vol. 41, 1994, pages 167 - 175, XP000653564, ISSN: 0300-9564 *

Also Published As

Publication number Publication date
HUP9902482A2 (en) 2002-04-29
HU9902482D0 (en) 1999-10-28
AU6585600A (en) 2001-02-13
WO2001007033A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
TR200103493T2 (en) Metalloprotease inhibitors
SE9903759D0 (en) Pharmaceutically active compounds
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
AU782631C (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
NO20013958L (en) Medication for the treatment of high blood pressure
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
EP1602645A4 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
NO951147D0 (en) Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
NO20013414D0 (en) New use of melagatran
WO1997009317A3 (en) Optically active phenyl pyrimidine derivative as analgesic agent
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
HK1045260A1 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use.
WO2001007033A3 (en) Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline
NO20012541D0 (en) Use of phosphonomauric acid derivatives for the treatment of infections
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
EP1143990A3 (en) Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
AU2253197A (en) Novel substituted N-Methyl-N-(4-(4-(1H-benzimidazol- 2-yl){1,4}diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
ID20165A (en) USE OF ACID 2- (3,4-DIMETOXICINAMOIL) AMINOBENZOAT FOR MAKING MEDICINES FOR TREATMENT OR PREVENTION OF RESTENOSIS
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
WO2001007029A3 (en) Substituted guanidines and the use thereof
AU2154901A (en) Simplified administration of alpha-lipoic acid or derivatives thereof
AU1423701A (en) Alkaline salts on n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone) -n'-isonicotinoylhydrazide, which can possess antimicrobial and immunothrope activity, the method for producing these salts, their use as immunomodulator and pharmaceutical

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP